Alkermes plc (NASDAQ:ALKS) SVP Christian Todd Nichols Sells 5,208 Shares of Stock

Alkermes plc (NASDAQ:ALKS) SVP Christian Todd Nichols sold 5,208 shares of the business’s stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $29.15, for a total value of $151,813.20. Following the transaction, the senior vice president now owns 60,703 shares in the company, valued at approximately $1,769,492.45. This represents a 7.90 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Alkermes Stock Up 0.2 %

NASDAQ:ALKS opened at $29.32 on Thursday. Alkermes plc has a 52 week low of $22.22 and a 52 week high of $32.88. The stock’s fifty day moving average is $27.98 and its two-hundred day moving average is $26.47. The stock has a market capitalization of $4.74 billion, a price-to-earnings ratio of 15.04, a price-to-earnings-growth ratio of 0.98 and a beta of 0.47. The company has a quick ratio of 3.03, a current ratio of 3.45 and a debt-to-equity ratio of 0.22.

Institutional Investors Weigh In On Alkermes

Several institutional investors and hedge funds have recently modified their holdings of ALKS. Franklin Resources Inc. grew its position in Alkermes by 2.5% in the 3rd quarter. Franklin Resources Inc. now owns 120,006 shares of the company’s stock valued at $3,486,000 after acquiring an additional 2,903 shares in the last quarter. Tidal Investments LLC acquired a new stake in shares of Alkermes during the third quarter worth about $1,098,000. Wilmington Savings Fund Society FSB purchased a new position in shares of Alkermes in the third quarter valued at approximately $582,000. Sanctuary Advisors LLC boosted its stake in shares of Alkermes by 254.5% in the third quarter. Sanctuary Advisors LLC now owns 32,791 shares of the company’s stock valued at $944,000 after purchasing an additional 23,541 shares during the period. Finally, Hohimer Wealth Management LLC acquired a new position in shares of Alkermes in the third quarter valued at approximately $315,000. Hedge funds and other institutional investors own 95.21% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the company. HC Wainwright reiterated a “neutral” rating and set a $37.00 price objective on shares of Alkermes in a research report on Friday, October 25th. JPMorgan Chase & Co. lowered their price target on shares of Alkermes from $32.00 to $26.00 and set a “neutral” rating on the stock in a research report on Friday, October 25th. Piper Sandler restated an “overweight” rating and set a $37.00 price objective (down from $38.00) on shares of Alkermes in a research report on Friday, October 25th. Cantor Fitzgerald decreased their target price on shares of Alkermes from $48.00 to $43.00 and set an “overweight” rating on the stock in a report on Friday, October 25th. Finally, Mizuho raised their price target on shares of Alkermes from $35.00 to $40.00 and gave the stock an “outperform” rating in a report on Wednesday, November 13th. One research analyst has rated the stock with a sell rating, three have given a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $35.42.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.